Revolution Medicines (RVMD) Net Equity Issued and Repurchased (2019 - 2026)

Revolution Medicines' Net Equity Issued and Repurchased history runs 7 years deep, the most recent figure standing at $141.9 million for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $141.9 million in Q1 2026; TTM through Mar 2026 was $201.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $347.9 million, up 484.71% from the prior year.
• Net Equity Issued and Repurchased grew to $141.9 million in Q1 2026 per RVMD's latest filing, from $59.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $323.7 million in Q1 2023 and bottomed at $59.5 million in Q4 2024.
• The 4-year median for Net Equity Issued and Repurchased is $141.9 million (2026), against an average of $167.1 million.